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Abstract: Atrial fibrillation (AF) is a global disease with rapidly rising incidence and prevalence. It is
associated with a higher risk of stroke, dementia, cognitive decline, sudden and cardiovascular death,
heart failure and impairment in quality of life. The disease is a major burden on the healthcare system.
Paroxysmal AF is typically managed with medications or endocardial catheter ablation to good
effect. However, a large proportion of patients with AF have persistent or long-standing persistent
AF, which are more complex forms of the condition and thus more difficult to treat. This is in part
due to the progressive electro-anatomical changes that occur with AF persistence and the spread of
arrhythmogenic triggers and substrates outside of the pulmonary veins. The posterior wall of the
left atrium is a common site for these changes and has become a target of ablation strategies to treat
these more resistant forms of AF. In this review, we discuss the role of the posterior left atrial wall in
persistent and long-standing persistent AF, the limitations of current endocardial-focused treatment
strategies, and future perspectives on hybrid epicardial–endocardial approaches to posterior wall
isolation or ablation.
Keywords: persistent atrial fibrillation; posterior wall; hybrid ablation; convergent ablation
1. Introduction
Atrial fibrillation (AF) is the most commonly diagnosed sustained cardiac dysrhythmia
and is characterised by rapid and irregular activation of the atria. It is associated with an
increased risk of ischemic stroke, heart failure and mortality and can have a substantial
impact on quality of life. Atrial fibrillation can be paroxysmal, lasting 7 days or less
with or without intervention, or be continuous beyond 7 days (persistent, PersAF) or
beyond 12 months (long-standing persistent, LSPersAF) [1]. Permanent AF is the term
used for long-standing persistent AF when any attempt to restore sinus rhythm has been
abandoned or has proved impossible. As each episode of AF continues, progressive electro-
anatomical remodelling occurs that may serve to perpetuate and sustain AF, known as ‘AF
begets AF’ [2]. Therefore, it is not surprising that treatment strategies vary in effectiveness
depending on the extent and duration of AF.
Overall, optimal AF management should include a holistic, comprehensive, multidisci-
plinary approach that collectively considers modifiable risk factors, stroke prevention, and
patient- and symptom-focused rate and rhythm control [3] (Figure 1). Using this approach,
known as the AF Better Care (ABC) pathway, AF is managed with lifestyle modifications
to address risk factors such as obesity and hypertension, and medical therapy which can
include anticoagulation for stroke prevention as well as rate and rhythm control drugs
depending on the patient and symptoms [1,3]. When antiarrhythmic drugs fail or are
intolerable, ablation is recommended. This typically takes form as standalone endocardial
catheter ablation or as surgical ablation if performed concomitantly with a primary cardiac
surgical procedure. In both cases, pulmonary vein isolation (PVI) is paramount, although
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other regions often emerge as potential substrates in PersAF [4]. One of these regions,
arguably the most influential after the pulmonary veins (PVs), is the posterior wall of
the left atrium, which is known to generate AF triggers and is subject to electrical and
structural changes that occur with the persistence of AF. However, this region is where
endocardial catheter ablation is more limited in its capacity to comprehensively address
the AF substrate owing to the elevated risk of collateral damage to adjacent structures
such as the oesophagus. This review aims to discuss the published literature on the role
of the left atrial posterior wall in PersAF and LSPersAF, outline practical limitations of
endocardial catheter ablation to safely and durably isolate the posterior wall and describe
the rationale for a hybrid epicardial–endocardial ablation strategy for silencing the PVI
and posterior wall.
Figure 1. Risk factors for perpetuation of AF. Modifiable risk factors are highlighted separately.
LSPersAF, long-standing persistent AF; LA, left atrium; PWD, p-wave duration; LVH, left ventricular
hypertrophy; BMI, body mass index; OSA, obstructive sleep apnoea; DM, diabetes mellitus.
2. Burden of Atrial Fibrillation
Atrial fibrillation was estimated to affect more than 43 million people worldwide in
2016, a figure that continues to rise every year, with observed increases during the last
few decades in associated disability and mortality [3]. Atrial fibrillation increases the risk
of stroke around five-fold [5], more so with multiple co-existing risk factors, and is also
associated with increased mortality [6] even within the first few months of diagnosis [7].
Atrial fibrillation can also overlap with heart failure in that it can exacerbate existing heart
failure or lead to tachycardia-induced cardiomyopathy in patients with chronic, poorly
managed AF. Therefore, the impact of AF on the global healthcare system is significant. In
addition, AF is associated with a decreased quality of life, which can be attributed to the
burden of symptoms, as well as the complex interplay with other patient comorbidities
commonly associated with AF [8]. In effect, treating the syndrome with AF is not only
aimed at reducing the risks of stroke and cardiac death but also decreasing AF burden and,
consequently, AF symptoms to improve patient quality of life.
3. Treatment of Paroxysmal Atrial Fibrillation
In a seminal 1998 paper, Häissaguerre and colleagues identified the PVs as the pri-
mary sites of arrhythmogenicity in paroxysmal AF and that these AF triggers could be
destroyed or isolated with radiofrequency ablation [9]. Favourable success rates have been
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demonstrated for endocardial catheter ablation focused on the PVs for the treatment of
drug-refractory paroxysmal AF [10], further supported by advancements in catheter-based
radiofrequency, cryoballoon and other technologies [11,12].
4. Paroxysmal vs. Persistent Atrial Fibrillation: Differences in Treatment Outcomes
The consistent clinical success of endocardial catheter ablation in paroxysmal AF is not
paralleled in persistent and long-standing persistent forms of AF. The discrepancy between
paroxysmal and non-paroxysmal AF outcomes is well-evidenced by long-term results
of endocardial radiofrequency ablation in these subgroups. With a median follow-up of
4.8 years after circumferential PVI, Ouyang et al. reported 46.6% of 161 patients with
paroxysmal AF were free from atrial arrhythmia recurrence after a single procedure, and
this success rose to 79.5% with multiple procedures (median 1: range 1–3) [13]. However, in
long-standing PersAF, with a median follow-up of 4.7 years, the same investigators reported
20.3% of 202 patients were free from arrhythmia recurrence after PVI with additional
CFAE/linear ablation [14]. After multiple procedures (median 2, range 1–5), 45% of patients
with LSPersAF were in sinus rhythm. A comprehensive meta-analysis of persistent and
long-standing PersAF treatment outcomes reported similarly disappointing results with
much shorter follow-up times [15].
One explanation for the suboptimal effectiveness of PVI in non-paroxysmal AF is that
areas outside of the PVs can drive and act as substrates as AF continues [16]. It has been
well-documented that AF triggers are present outside of the PVs [17,18]. While extra-PV
triggers may be present in paroxysmal AF, the majority of triggers are located in and
around the PVs (Figure 2); this may, at least in part, explain why PV isolation alone is
more effective in treating this type of AF [19]. However, as AF becomes persistent, there is
a shift towards extra-PV triggers for atrial tachyarrhythmias and, given the progressive
electrophysiological and structural changes that occur with the persistence of AF, these
extra-PV regions may be appropriate substrates for ablation in PersAF and LSPersAF.
Having said that, what and how to ablate in PersAF and LSPersAF is still unclear. Data
from the STAR-AF II trial appeared to show that additional endocardial ablation utilising
CFAEs or certain linear lesions (roof and mitral lines) adjunctive to PVI did not improve
clinical outcomes over PVI alone in PersAF [20]; although, dedicated posterior wall ablation
was not specifically tested in this study.
Figure 2. Triggers and substrates for PAF vs. PersAF. In PAF, the majority of these are located within
and around the PVs, whereas in PersAF there are many more non-PV locations, especially in the
posterior wall (between the four PVs and below the lower PVs). LA, left atrium; LAA, left atrial
appendage; RA, right atrium; RAA, right atrial appendage; SVC, superior vena cava; IVC, inferior
vena cava.
The left atrial posterior wall has been shown to house the highest proportion of non-
PV triggers. Lin et al. reported 38% of non-PV ectopic beats emanated from the posterior
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wall [17]. Additionally, with continued PersAF, the left atrial posterior wall is the most
common non-PV site to contain AF re-entrant drivers [16]. In the next section, we review
the unique arrhythmogenic properties of the posterior wall that underscore the rationale
for its role in PersAF and LSPersAF.
5. The Posterior Wall of the Left Atrium in Non-Paroxysmal Atrial Fibrillation
5.1. Intrinsic Features
The left atrial posterior wall has several inherent anatomic and electrophysiological
properties that are conducive to arrhythmogenicity. When these factors are combined
with the structural changes that develop with more prolonged episodes of AF (see next
section on ‘Effects of prolonged atrial fibrillation on posterior wall’), the posterior wall
then emerges as one of the key regions in the pathophysiology of PersAF. The posterior
wall is derived embryonically from the same tissue as the pulmonary veins [21]. Between
approximately 6–8 weeks of gestation, the common pulmonary vein, lined with mediastinal
myocardium distinct from the primary myocardium that lines systemic venous structures,
bifurcates and becomes incorporated into the left atrial wall [22]. Of note, the mediastinal
myocardium is composed of fast-conducting cells compared to the slower conducting cells
of the primary myocardium. Given the shared tissue origin with the pulmonary veins, it is
not surprising then that the posterior left atrial wall is also a site of AF triggers and plays a
role in sustaining PersAF.
Myocytes within the left atrial posterior wall have unique electrophysiological proper-
ties that may be intrinsically suited to initiate or sustain AF. These cells are characterised by
having larger late sodium currents and smaller potassium currents [23]. The intracellular
calcium transient and content within the sarcoplasmic reticulum are high. In effect, the cells
of the posterior wall have (i) a low resting membrane potential; (ii) short action potential
duration; (iii) the shortest refractory period of any cell in the heart. Taken together, these
cellular characteristics make the posterior wall prone to misfiring.
Other structural aspects of the posterior wall can contribute to AF initiation and facili-
tate re-entry. The myocardial fibres in the left atrial posterior wall, particularly near the
junction with the pulmonary veins, have a heterogenous orientation with respect to each
other [24]. As a consequence, non-uniform anisotropy can occur in which conduction ve-
locity and depolarisation differ between adjacent tissues, including the transition between
the epicardial and endocardial layers. Subsequently this can lead to delayed conduction,
unidirectional block and, thus, local re-entry.
The autonomic nervous system is a key player in the initiation and sustainment of AF.
The posterior wall of the left atrium has the highest density of autonomic neurons in the
heart [25]. Ganglionated plexi are groups of autonomic neurons embedded in epicardial
fat pads, and some of the ganglionated plexi are located at the posterior left atrium, near
the pulmonary veins. Ganglionated plexi are thought to contribute to AF and at times are
adjunctive targets in ablation procedures.
5.2. Effects of Prolonged Atrial Fibrillation on Posterior Wall
As described above, there are intrinsic functional and anatomical characteristics of
the left atrial posterior wall that make it prone to the initiation and maintenance of AF.
Once AF occurs and persists over time, progressive changes in the left atrium then serve to
propagate and further sustain AF. As such, the left atrial posterior wall is acknowledged as
a key AF substrate in persistent forms of the disease. The development of fibrosis is thought
to be a contributing factor to the propagation and persistence of AF. Fibrosis can develop
due to other cardiac abnormalities or health conditions that are coincident with AF, as well
as aging. Fibroblasts comprise 50–70% of cardiac cells [25], and their function is to compose
and dynamically maintain the heart’s scaffold [26]. These fibroblasts can differentiate
into myofibroblasts under various pathologic conditions, including inflammation and
mechanical overload. Myofibroblasts, in turn, produce, turn over and deposit collagen
and other extracellular matrix components, which lead to the hardening and scarring of
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cardiac tissue. This fibrotic tissue can slow conduction, serve as a unidirectional block
and contribute to macro re-entry [27]. Cochet et al. demonstrated through MRI delayed
enhancement that fibrosis tends to develop on the posterior left atrium [28]. This may be in
part due to chronic, increased stress in the regions adjacent to the pericardial reflections
that anchor the posterior heart to the chest wall [29]. Additionally, increased pressure
and dilation of the left atrium due to prolonged AF leads to stretching, followed by
inflammation and leading to fibrosis [30].
The accumulation of epicardial fat on the posterior wall can also contribute to AF in
two ways. Firstly, adipose tissue produces inflammatory signals that support remodelling
and fibrosis [31]. Secondly, animal studies have suggested infiltration of epicardial adipose
tissue into the myocardium may create tissue disorganisation that can serve as a substrate
for aberrant conduction [32]. Areas of abnormal conduction in the posterior left atrium
have been shown to be associated with adjacent epicardial adipose tissue in obese patients
with AF [33].
5.3. Difficulties with Endocardial Ablation of Posterior Wall
Given the evidence for the posterior wall as an AF substrate, both in triggering and
sustaining AF, the posterior wall has been explored as a target of radiofrequency and
cryoablation to improve clinical outcomes in AF, particularly PersAF and LSPersAF. This
is evident from the Cox-Maze IV surgical ablation lesion set, which isolates the posterior
wall of the left atrium with epicardial ablation lines on the right and left pulmonary vein
antrum followed by roof and floor ablations anchored to the left atriotomy [34]. However,
Cox-Maze IV is typically performed concomitantly with open cardiac surgeries, limiting its
reach to patients who do not need or want an open procedure.
Endocardial catheter isolation of the left atrial posterior wall has been studied with
both radiofrequency and cryothermal ablation (Table 1). The majority of these studies
included only patients with PersAF and LSPersAF, which is in line with current guideline
recommendations when considering posterior wall isolation in conjunction with PVI [1].
Meta-analyses of a few randomised and observational comparison studies have suggested
an overall benefit of endocardial posterior wall ablation compared to pulmonary vein
isolation alone in PersAF [35,36], but results of the individual studies, including the ran-
domised clinical trials [37–39], are mixed (Table 1). This may, in part, be due to the lack
of a standardised approach to posterior wall isolation, which is evidenced by the various
lesion sets used in published studies. These approaches to posterior wall isolation include a
single ring around the PVs and posterior left atrium [39], linear lesions (left atrial roof and
posterior-inferior) to create the so-called posterior ‘box’ lesion [37,38,40,41], or extensive
point-by-point radiofrequency [42] or segmental cryoballoon ablation [43,44] to debulk the
posterior wall. Adjunctive lesions also vary among these studies.
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Table 1. Summary of select studies evaluating addition of posterior wall isolation to pulmonary vein isolation.
Study AF Type Primary Energy Source
Ablation Strategies
Summarised Outcomes
PVI Group PVI + PW Group
Aryana et al. 2018
Non-randomised PersAF Cryoballoon
• PVI
• >50% received CTI by
irrigated RF
• PVI
• Segmental LAPW ablation
• >50% received CTI by irrigated RF
• Point-by-point RF as needed if isolation
not achieved
• 32.4% had adjunct RF to complete
PVI + PW
• 1-year freedom from atrial arrhythmias
was 74% in PVI + PW vs. 48% in PVI
(p < 0.001) 1
Bai et al. 2016
Non-randomised PersAF Irrigated RF
• PVAI
• SVC ablation if needed
• Verification of PVI at
3 months and reablation
if needed until isolated
• PVAI to the coronary sinus and left side of
interatrial septum
• Extensive PW ablation
• SVC ablation if needed
• Verification of PVI + PWI at 3 months and
reablation if needed
• 1-year freedom from atrial arrhythmia off
AADs was 65% in PVI + PW group vs.
20% in PVI group (p < 0.001); benefit
maintained through 3 years
Tokioka et al. 2020







• AF recurrence rate was 31.1% in PVI + PW
vs. 47.3% in PVI at median 19 mths
(p = 0.35)
• Recurrence of PersAF was 5.6% vs.
20.9% (p = 0.002); no significant
differences in recurrent PAF or
atrial tachycardia













• Freedom from atrial arrhythmias at mean
9.8 mths follow-up was 55% in each group
(p = 0.943)
• No significant difference in outcomes
between ablation strategies in
Pers/LSPersAF subanalysis










• Single ring isolation
• MTI (54%)
• CTI
• 2-year AF-free survival was 74% in
PVI + PW vs. 61% in PVI (p = 0.031)
• 2-year atrial arrhythmia-free survival was
not significantly different
Kim et al. 2015
Randomised PersAF Irrigated RF
• Circumferential PVI
• Roof line




• Anterior wall line
• CTI
• Inferior line
• 12-month cumulative recurrence was
16.7% in PVI + PW vs. 36.7% for PVI alone
(p = 0.02)
Lee et al. 2019
Randomised
26.7% PersAF







• Point ablation as needed
• Anterior line as per physician discretion
• Freedom from AF off AADs (mean
16.2 mths) was 55.9% in PVI + PW vs.
50.5% in PVI (p = 0.522)
• Recurrence rate was 26.5% in PVI + PW vs.
23.8% in PVI (p = 0.78).
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Table 1. Cont.
Study AF Type Primary Energy Source
Ablation Strategies
Summarised Outcomes
PVI Group PVI + PW Group





• CTI by RF
• Point-by-point RF as
needed for PVI
• 7.3% had adjunct
RF ablation
• PVI
• Segmental LAPW ablation
• CTI by RF
• Point-by-point RF as needed for PVI + PW
• 45.5% had adjunct RF ablation
• 12-month AF recurrence was 25.5% in
PVI + PW vs. 45.5% in PVI (p = 0.028)
• 12-month atrial arrhythmia recurrence
was 34.5% in PVI + PW vs. 49.1% in PVI
(p = 0.12)
1 Percentages depicted in Kaplan–Meier curve in Aryana et al. 2018 as noted in Della Rocca et al. 2020; AAD: antiarrhythmic drugs; AF: atrial fibrillation; CTI: cavotriscupid isthmus; LSPersAF: long-standing
persistent AF; MTI: mitral isthmus; PAF: paroxysmal AF; PersAF: persistent AF; PVAI: pulmonary vein antrum isolation; PVI: pulmonary vein isolation; PW: posterior wall; RF: radiofrequency; SVC: superior
vena cava.
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In addition to a lack of standardised posterior wall ablation strategy, other practical
challenges limit the extent to which endocardial posterior wall isolation can be achieved
and thus may contribute to varied clinical outcomes. One major concern with endocardial
catheter ablation of the left atrial posterior wall is potential collateral damage. The tissue
of the posterior wall is thin, particularly at the superior aspect, in part to accommodate
the stress of limited cardiac motion at the pericardial reflections [45]. It has been shown
using post-mortem hearts that the posterior wall tissue is generally thinner in patients
with AF, with an overall mean thickness of ≤3 mm [45]. Endocardial catheters apply
ablative energy away from the heart towards the pericardium, therefore there are risks
of cardiac perforation and tamponade as well as thermal injury to the oesophagus and
other adjacent structures. Atrio-oesophageal fistula is the most devastating consequence
of oesophageal thermal injury. While the documented incidence is low (<0.1%) with
endocardial posterior wall ablation, the potential risk remains, and the consequences can
be fatal [46]. Oesophageal temperature monitoring during ablation may be used as an alert
for thermal injury; however, there are well recognised limitations such as the temperature
can continue to rise after ablation is stopped and the probe may cause oesophageal damage
by thermal effect. Consequently, despite the use of this device, atrio-oesophageal fistula
can still develop [47], limiting the widespread use of such an approach for monitoring.
Indeed, a recent randomised study demonstrated a similar rate of endoscopically-detected
oesophageal lesions following endocardial catheter ablation with and without the use of an
oesophageal temperature probe [48]. Additionally, aborting ablation due to an unexpected
rise in temperature may result in incomplete ablation lines and gaps. Reducing the power
and/or duration of energy delivery during ablation on the posterior wall is normally
undertaken to reduce the risk of collateral damage, but this also reduces the efficacy of
lesion formation. Taken together, active mitigation of thermal injury is important, yet it may
also contribute to incomplete isolation of the posterior wall and varied clinical outcomes.
Reported rates of acute and continued isolation of the posterior wall using endocardial
catheter ablation suggest there is difficulty in creating transmural and durable lesions. A
meta-analysis of endocardial posterior wall isolation found an acute procedural success rate
of 78% (95% CI, 59.4–94.4%) with results from box, single ring and debulking techniques
combined [35]. The same meta-analysis also reported a substantial rate of posterior wall
reconnections observed at repeat electrophysiology procedures for arrhythmia recurrence
after endocardial catheter ablation: the pooled rate of posterior wall reconnection was
63.1% (95% CI, 42.5–82.4%) [35]. Markman et al. assessed chronic posterior wall isolation
at repeat ablation after a single procedure of PVI and posterior wall ablation. They found a
40% rate of posterior wall reconnections in patients who experienced arrhythmia recurrence,
with most reconnections at the atrial roof and most recurrences classified as atrial flutter
in patients with failed posterior wall isolation [49]. Bai et al. reported 37.5% of patients
had posterior wall reconnections three months after a single endocardial posterior wall
debulking procedure [42]. In fact, four of the studies comparing PVI to PVI with posterior
wall isolation discussed herein suggest suboptimal durability of posterior wall isolation
using endocardial catheter ablation (Table 2).
Evidence of endocardial–epicardial dissociation in atrial fibrillation may also limit
the effectiveness of endocardial posterior wall isolation, especially when considered in the
context of suboptimal transmurality. Endocardial–epicardial dissociation, as evidenced by
asynchronous activation of the epicardial and endocardial surfaces, was initially demon-
strated in animal [50] and computational models [51]. More recently, real-time mapping
has shown there may be up to 50–55% asynchronous activation between the epicardial and
endocardial surfaces in patients with AF [52,53]. One contributing factor to endocardial–
epicardial dissociation in AF may be the presence of fibrosis in the epicardial layer, which
was first suggested by animal studies [54] and recently supported by computational mod-
elling with validation in a small number of patients [55]. The cumulative evidence for
endocardial–epicardial dissociation suggests that endocardial-only mapping and abla-
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tion may be insufficient to adequately address conduction abnormalities on both cardiac
surfaces in AF.
Table 2. Posterior wall (PW) connection rates in studies comparing pulmonary vein isolation (PVI) to PVI + PW isolation.
Study Posterior Wall Strategy Follow-Up Time Population Evaluatedfor Reconnection
Reconnection Rates in
PW Ablation Group
Bai et al. 2016 Debulking with RF 3-months All patients 37.5% 1
Lee et al. 2015 Linear ablation with RF 16.2 ± 8.8 months Recurrent patients 50%
Tamborero et al. 2009 Linear ablation with RF 9.8 ± 4.3 months Recurrent patients 67%
Tokioka et al. 2020 Linear ablation with RF 1–6 months Recurrent patients 65.2%
1 Includes pulmonary vein and PW reconnections; PVI: pulmonary vein isolation; PW: posterior wall; RF: radiofrequency.
5.4. Hybrid Epicardial–Endocardial Approach to Address Posterior Wall Silencing
In effect, there are three main challenges in the treatment of PersAF and LSPersAF:
(i) limited candidates for concomitant surgical ablation; (ii) limited effectiveness of catheter
ablation in non-paroxysmal AF; (iii) challenges with endocardial catheter ablation focused
on the left atrial posterior wall, which is a source of AF triggers and a substrate. These
issues prompted the development of hybrid epicardial–endocardial approaches to ablation.
Hybrid approaches combine minimally invasive epicardial ablation by a cardiothoracic
surgeon and endocardial ablation by an electrophysiologist to complete a transmural lesion
set that effectively isolates the pulmonary veins and left atrial posterior wall.
There are two general strategies for hybrid epicardial–endocardial ablation. The pri-
mary difference is the surgical epicardial ablation technique, including epicardial access,
ablation tools and posterior wall lesion set. Hybrid ablation can be achieved with totally
thoracoscopic (TT) epicardial ablation followed by endocardial ablation. In hybrid TT
ablation, surgical access to the pericardium is achieved thoracoscopically and the epicar-
dial lesion set is focused on PVI and creating a box lesion set across the posterior wall.
Endocardial ablation is performed by an electrophysiologist to complete PVI and address
gaps. The first report of this approach was published in 2011 [56]. Recent retrospective
studies have reported mid-term (2–3 year) outcomes ranging from 67–79% arrhythmia-free
survival off AADs in patients with PersAF and LSPersAF [57–59]. Safety and effectiveness
of hybrid TT ablation are being evaluated in two randomised clinical trials (NCT02441738,
NCT02695277) and one single-arm trial (NCT02393885).
In the other hybrid epicardial–endocardial approach, commonly referred to as the
hybrid Convergent procedure, the surgeon uses a single, small subxiphoid incision to gain
access to the pericardial space without the use of additional ports. It was initially proposed
in 2009 [60] and the ablation set has evolved over time. In early studies, an ex-Maze lesion
set was performed through a transabdominal, transdiaphragmatic approach [60]. A box
lesion set then became the preferred method to isolate the posterior wall. Since 2012,
epicardial posterior wall homogenization has been achieved with 2–3 rows of linear lesions
spanning between the pulmonary veins [61], which is another distinction from the TT
lesion set. Beginning in 2016, the pericardial space has been accessed via the subxiphoid
incision [62], eliminating the need to divide the central tendon of the diaphragm. Endo-
cardial mapping and ablation are subsequently performed by the electrophysiologist on
the same day, sequential day, or several weeks later, with the goal of ensuring PVI and
addressing any gaps following the epicardial procedure. Further, since there is recovery of
electrical conduction following epicardial ablation, it remains important to undertake both
components of the hybrid technique to achieve long-lasting, widespread transmurality [63].
Observational clinical outcomes from contemporary analyses have suggested favourable
outcomes with this technique [64–68], which were recently corroborated by the results of
the multi-centre, randomised controlled CONVERGE trial [69]. The trial compared hybrid
Convergent ablation with endocardial catheter ablation in PersAF and LSPersAF and met
its primary safety and effectiveness endpoints. Twelve-month freedom from atrial arrhyth-
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mias without new/increased doses of AADs was 67.7% with hybrid Convergent ablation
compared to 50.0% with catheter ablation (p = 0.036). Significantly better effectiveness off
AADs (53.5% vs. 32.0%, p = 0.013) and irrespective of AADs (76.8% vs. 60.0%, p = 0.033)
were also achieved with hybrid Convergent ablation. The 30-day major adverse event rate
with the hybrid Convergent procedure was 7.8% (vs 0.0% in the catheter arm, p = 0.0525),
primarily relating to inflammatory pericardial effusions. Of note, no cardiac perforations,
deaths or atrio-oesophageal fistulas occurred.
One important aspect of both hybrid ablation strategies is a collaborative, heart
team approach to patient management in order to optimise clinical outcomes and safely
mitigate risks [70].
6. Future Directions
Isolation of the left atrial posterior wall with a combination of epicardial and endocar-
dial ablation to increase the likelihood of durable, transmural lesion has shown promising
results in observational studies during the last decade as well as in a randomised controlled
trial. More recently, these studies have described outcomes using a subxiphoid approach
to reach the posterior left atrium, and additional studies dedicated to this approach will be
important. Concomitant application of the AtriClip®, the most widely employed left atrial
appendage exclusion device, is gaining popularity [4] and future studies should assess the
precise impact on AF outcomes of including this technique. Another endpoint of interest
for a hybrid approach is evaluating the length of stay for comparison with other minimally
invasive surgical ablation approaches. For example, in our experience, we have seen rapid
recovery after hybrid Convergent ablation, with a median length stay of 1 day, in contrast
to recovery times for patients who undergo totally thoracoscopic Maze procedures, who
typically require several days prior to discharge.
7. Conclusions
The left atrial posterior wall is likely an important driver and substrate as AF pro-
gresses and, as such, its isolation has been explored during AF ablation procedures to
improve clinical outcomes in PersAF and LSPersAF. Surgical-only approaches to isolate
the posterior wall are limited by invasiveness and patient eligibility for a concomitant
procedure. Endocardial ablation alone to isolate the posterior wall has yielded mixed
results in PersAF and LSPersAF. Electrophysiological differences between the endocardium
and epicardium may not be safely addressable with an endocardial approach alone. The
combination of the two concepts into a hybrid electrophysiological–surgical collabora-
tion, such as in the Convergent procedure, may help to optimise lesion durability and
transmurality to effectively isolate the posterior wall.
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